Eledon Pharmaceuticals, Inc.
ELDN
$3.55
-$0.03-0.84%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/9/2026
-
Tickeron - Stocks
6/8/2026
-
Globe Newswire
6/4/2026
-
Globe Newswire
6/4/2026
-
Tickeron - Stocks
6/3/2026
-
Tickeron - Stocks
5/29/2026
-
Zacks Investment Research
5/29/2026
-
Tickeron - Stocks
5/27/2026
-
TipRanks Financial Blog
5/27/2026
-
Globe Newswire
5/22/2026
-
TipRanks Financial Blog
5/21/2026
-
Tickeron - Stocks
5/20/2026
-
Globe Newswire
5/19/2026
-
Tickeron - Stocks
5/18/2026
-
TipRanks Financial Blog
5/15/2026
-
The Cerbat Gem
5/13/2026
-
Globe Newswire
5/6/2026
-
MarketBeat
5/1/2026
-
TipRanks Financial Blog
5/1/2026
-
Tickeron - Stocks
4/30/2026
-
Globe Newswire
4/30/2026
-
Tickeron - Stocks
4/24/2026
-
Tickeron - Stocks
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts
4/21/2026
-
MarketBeat
4/20/2026
-
Yahoo! Finance: News
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 13, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
949 238 8090
Address
19800 MacArthur Boulevard
Irvine, CA 92612
Irvine, CA 92612
Country
Year Founded
--
Business Description
Sector
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect...
more